Form 144 REPLIMUNE GROUP For: 9 November
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Replimune Group Inc (REPL)
Track today's live Replimune (REPL) share price, performance and key data on this page with our current NASDAQ:REPL stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Replimune share price on the NASDAQ exchange. Use the dropdown to switch exchange for the REPL share price, head to our technical summary section, which provides analysis on Replimune share price buy/sell indicators using real-time data (or discuss the Replimune (REPL) stock price today with other investors in the Replimune NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:REPL share price (ISIN: US76029N1063) to enhance your trading decisions with our free investment tools and resources.
What Is the Replimune Group Inc Share Price Today?
The Replimune share price today is 21.35.
What Is the Stock Symbol for Replimune Group Inc
The stock symbol (or 'ticker') for Replimune Group Inc is "REPL."
What Stock Exchange Does Replimune Group Inc Trade On?
Replimune Group Inc is listed and trades on the NASDAQ stock exchange.
Is Replimune Group Inc a Good Stock to Buy?
Determining whether Replimune (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:REPL share price (ISIN: US76029N1063) to enhance your trading decisions with our free investment tools and resources.
What Is the Replimune Group Inc Share Price Today?
The Replimune share price today is 21.35.
What Is the Stock Symbol for Replimune Group Inc
The stock symbol (or 'ticker') for Replimune Group Inc is "REPL."
What Stock Exchange Does Replimune Group Inc Trade On?
Replimune Group Inc is listed and trades on the NASDAQ stock exchange.
Is Replimune Group Inc a Good Stock to Buy?
Determining whether Replimune (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
21.35
-0.43(-1.97%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.48
22.00
52 wk Range
1.50
23.54
REPL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.4822.00
52 wk Range
1.5023.54
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
REPL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
23.33
Upside
+9.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
- Form 144 REPLIMUNE GROUP For: 30 October
- Investing.com
Replimune Group stock hits 52-week high at 21.27 USD- Investing.com
Replimune Group stock hits 52-week high at 16.39 USD- Investing.com
- Form 144 REPLIMUNE GROUP For: 9 November
- Investing.com
- Replimune Group stock hits 52-week high at 21.27 USD
- Investing.com
Form 144 Replimune Group Inc. For: 2 November- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
7 Buy
0 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 23.33
(+9.29% Upside)
Replimune Group Inc SWOT Analysis
FDA Setback | Replimune faces regulatory hurdles as FDA issues Complete Response Letter for RP1, impacting near-term prospects and pipeline development |
Financial Outlook | Negative EPS projections and $397.3M market cap reflect challenges, yet cash runway suggests stability amid ongoing clinical trials |
Oncology Potential | Explore Replimune's diverse pipeline beyond RP1, including RP2 and expanded indications in skin cancers and organ transplants |
Market Valuation | Analyst targets range from $3 to $17, with recent downgrades reflecting regulatory uncertainty and potential for future growth |
Replimune Group Inc Earnings Call Summary for Q2/2027
- Replimune reported Q2 FY2026 loss of $0.54/share, beating consensus of $0.75 by 28%; zero revenue vs. $1M forecast due to timing.
- TUDRIQEV commercial shipments began early October after quarter-end; over 70% of 200 target accounts engaged, 15+ institutions prescribing.
- Cash position strengthened to $307.8M from $141M August offering; runway exceeds 12 months with commercial organization nearly fully staffed.
- First product revenue expected in Q3 FY2026; no specific guidance provided. List price set at $450K per treatment course before rebates.
- Permanent J-code anticipated by April 2027 to broaden adoption; company plans to double prescribing accounts by end of 2026.
Last Updated: 28/10/2026, 12:46
Read Full TranscriptEarnings
Latest Release
28/10/2026
EPS / Forecast
-0.54 / -0.75
Revenue / Forecast
-- / 1M
Compare REPL to Peers and Sector
Metrics to compare | REPL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipREPLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.4x | −1.9x | −0.2x | |
PEG Ratio | −0.38 | −0.04 | 0.00 | |
Price/Book | 9.8x | 2.2x | 2.6x | |
Price / LTM Sales | - | 9.9x | 2.8x | |
Upside (Analyst Target) | 9.8% | 136.8% | 60.5% | |
Fair Value Upside | Unlock | 11.7% | 7.8% | Unlock |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Replimune (NASDAQ: REPL) Share Price Today?
The Replimune stock price today is 21.35 USD.
What Stock Exchange Does Replimune (REPL) Trade On?
Replimune is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Replimune?
The stock symbol (also called a 'ticker') for Replimune is "REPL."
What Is the Current Replimune Market Capitalisation?
As of today, Replimune (NASDAQ: REPL) market cap is 2.02B USD.
What Is Replimune's (REPL) Earnings Per Share (TTM)?
The Replimune EPS is currently -2.78 (Trailing Twelve Months).
When Is the Next Replimune Earnings Date?
Replimune's next earnings report will be released on 02/02/2027.
Is REPL a Buy or Sell From a Technical Analyst Perspective?
Based on today's Replimune moving averages and other technical indicators, the daily buy/sell signal for REPL stock is Strong Buy.
How Many Times Has Replimune Stock Split?
Replimune has split 0 times. (See the REPL stock split history page for full effective split date and price information.)
How Many Employees Does Replimune Have?
Replimune has 465 employees, based on their latest Companies House report.
What is the current trading status of Replimune (NASDAQ: REPL)?
As of 12/11/2026, Replimune (REPL) is trading at a share price of 21.35 USD, with a previous close of 21.78 USD. The stock has fluctuated within a day range of 20.48 USD to 22.00 USD, while its 52-week range spans from 1.50 USD to 23.54 USD.
What Is Replimune (REPL) Price Target According to Analysts?
The average 12-month price target for Replimune is 23.33 USD, with a high estimate of 31 USD and a low estimate of 14 USD. 7 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +9.29% Upside potential.
What Is the REPL Premarket Price?
REPL's last pre-market stock price is 21.40 USD. The pre-market share volume is 6,650.00, and the stock has decreased by -0.38, or -1.74%.
What Is the REPL After Hours Price?
REPL's last after hours stock price is 21.76 USD, the stock has decreased by -0.02, or -0.09%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.